A Phase 2 interventional study of Fostamatinib in lung transplant patients with antibodies

Study Description

Testing a drug called Fostamatinib to help prevent rejection in lung transplant patients who have developed antibodies against their new lungs

Study Details

Registry ID:

NCT06948097

Conditions:

Lung Transplantation

Phase:

Phase 1

Target Enrollment:

30 participants

Start Date:

October 5, 2026

Age Range:

18–99 years

Healthy Volunteers:

No

Study Locations (5 sites)

• Johns Hopkins University School of Medicine
  Baltimore, MarylandUnited States, United States
• National Heart, Lung and Blood Institute (NHLBI)
  Bethesda, MarylandUnited States, United States
• Inova Health System Foundation
  Falls Church, VirginiaUnited States, United States
• University of Utah Health
  Salt Lake City, UtahUnited States, United States
• Stanford University School of Medicine
  Stanford, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →